title: Effect of chemotherapy for luminal a breast cancer.
abstract: BACKGROUND
  The addition of chemotherapy to endocrine therapy for luminal A breast cancer generally provides little benefit. However, the least benefit of chemotherapy in all patients with luminal A breast cancer is controversial.
  
  
  METHODS
  This was a retrospective study of 140 patients with luminal A breast cancer who underwent surgery at Tottori University Hospital between 2001 and 2010. Luminal A breast cancer was defined as positive for estrogen receptors and/or progesterone receptors and negative for human epidermal growth factor 2. Postoperative endocrine therapy was given to all patients. The prognostic values of age, tumor size, presence of lymphovascular invasion and lymph node status were evaluated. In addition, the prognostic value of chemotherapy for patients with identified risk factors affecting relapse-free survival and overall survival was evaluated.
  
  
  RESULTS
  Tumor size greater than 2 cm and positive lymph node status were factors significantly affecting relapse-free survival. There were no factors significantly affecting overall survival. There was no significant difference in the relapse-free survival of patients with tumor size greater than 2 cm and/or positive lymph node status who either received chemotherapy or not. However, the relapse event was earlier in patients with tumor size greater than 2 cm and positive lymph node status who did not receive chemotherapy than in those who received chemotherapy.
  
  
  CONCLUSIONS
  Chemotherapy could provide little benefit to patients with luminal A breast cancer. However, chemotherapy may bring them longer relapse-free periods.
authors.affiliation: Clinic of Surgery, Tottori Prefectural Kosei Hospital, Kurayoshi 682-0804, Japan ; †Clinical Department of Mammoendocrinology, Tottori University Hospital, Yonago 683-8504, Japan.
authors.forename: Naotaka
authors.initials: N
authors.lastname: Uchida
authors.forename: Takako
authors.initials: T
authors.lastname: Suda
authors.forename: Kiyosuke
authors.initials: K
authors.lastname: Ishiguro
keywords: breast cancer; chemotherapy; luminal A
references.citation: N Engl J Med. 2004 Dec 30;351(27):2817-26
references.pmid: 15591335
references.citation: J Clin Oncol. 2003 Mar 15;21(6):976-83
references.pmid: 12637460
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1168-76
references.pmid: 19204205
references.citation: Nature. 2000 Aug 17;406(6797):747-52
references.pmid: 10963602
references.citation: Ann Oncol. 2011 Aug;22(8):1736-47
references.pmid: 21709140
references.citation: Clin Cancer Res. 2005 Aug 15;11(16):5678-85
references.pmid: 16115903
references.citation: J Clin Oncol. 2005 Jun 1;23(16):3686-96
references.pmid: 15897552
references.citation: J Clin Oncol. 2008 Feb 10;26(5):721-8
references.pmid: 18258979
references.citation: JAMA. 2006 Jun 7;295(21):2492-502
references.pmid: 16757721
references.citation: Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8
references.pmid: 12917485
references.citation: Mod Pathol. 2010 Feb;23(2):270-5
references.pmid: 19946260
references.citation: J Clin Oncol. 2006 Aug 10;24(23):3726-34
references.pmid: 16720680
references.citation: Eur J Surg Oncol. 2011 Oct;37(10):876-82
references.pmid: 21824742
references.citation: N Engl J Med. 2007 Oct 11;357(15):1496-506
references.pmid: 17928597
references.citation: Ann Oncol. 2009 Aug;20(8):1319-29
references.pmid: 19535820